FRESH™ 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology
Open Access
- 1 December 2023
- journal article
- research article
- Published by AIP Publishing in APL Bioengineering
- Vol. 7 (4) , 046113
Abstract
There is critical need for a predictive model of human cardiac physiology in drug development to assess compound effects on human tissues. In vitro two-dimensional monolayer cultures of cardiomyocytes provide biochemical and cellular readouts, and in vivo animal models provide information on systemic cardiovascular response. However, there remains a significant gap in these models due to their incomplete recapitulation of adult human cardiovascular physiology. Recent efforts in developing in vitro models from engineered heart tissues have demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure. Here, we advance this paradigm by implementing FRESH™ 3D bioprinting to build human cardiac tissues in a medium throughput, well-plate format with controlled tissue architecture, tailored cellular composition, and native-like physiological function, specifically in its drug response. We combined hiPSC-CMs, endothelial cells, and fibroblasts in a cellular bioink and FRESH™ 3D bioprinted this mixture in the format of a thin tissue strip stabilized on a tissue fixture. We show that cardiac tissues could be fabricated directly in a 24-well plate format were composed of dense and highly aligned hiPSC-CMs at >600 million cells/mL and, within 14 days, demonstrated reproducible calcium transients and a fast conduction velocity of ∼16 cm/s. Interrogation of these cardiac tissues with the β-adrenergic receptor agonist isoproterenol showed responses consistent with positive chronotropy and inotropy. Treatment with calcium channel blocker verapamil demonstrated responses expected of hiPSC-CM derived cardiac tissues. These results confirm that FRESH™ 3D bioprinted cardiac tissues represent an in vitro platform that provides data on human physiological response.Keywords
Funding Information
- Small Business Innovation Research (1R43HL160407-01)
This publication has 65 references indexed in Scilit:
- Regulation of Cardiac L-Type Ca 2+ Channel Ca V 1.2 Via the β-Adrenergic-cAMP-Protein Kinase A PathwayCirculation Research, 2013
- Simultaneous Voltage and Calcium Mapping of Genetically Purified Human Induced Pluripotent Stem Cell–Derived Cardiac Myocyte MonolayersCirculation Research, 2012
- Pluripotent stem cell-derived cardiac tissue patch with advanced structure and functionBiomaterials, 2011
- Estimating the Risk of Drug-Induced Proarrhythmia Using Human Induced Pluripotent Stem Cell–Derived CardiomyocytesToxicological Sciences, 2011
- A Review of Three-Dimensional In Vitro Tissue Models for Drug Discovery and Transport StudiesJournal of Pharmaceutical Sciences, 2011
- Development of a Drug Screening Platform Based on Engineered Heart TissueCirculation Research, 2010
- Is Phospholamban or Troponin I the “Prima Donna” in β-Adrenergic Induced Lusitropy?Circulation Research, 2007
- Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissueBiotechnology and Bioengineering, 2005
- Force–frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevanceEuropean Journal of Pharmacology, 2004
- Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy. Functional evidence for alterations in intracellular Ca2+ handling.Journal of Clinical Investigation, 1996